|
|
|
| May. 16, 2012 |
Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
|
| May. 16, 2012 |
Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer
|
| May. 11, 2012 |
Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
|
| May. 9, 2012 |
Cancer Support Community Launches National Program to Assist Patients With Cancer, Make Informed Decisions About Care
|
| May. 4, 2012 |
Amgen to Present at the Baird Growth Stock Conference
|
| May. 3, 2012 |
Amgen to Present at the Deutsche Bank 37th Annual Healthcare Conference
|
| May. 3, 2012 |
CURE Magazine Announces Winner of the 2012 Extraordinary Healer Award for Oncology Nursing
|
| May. 1, 2012 |
Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
|
| Apr. 26, 2012 |
Amgen Receives Complete Response Letter From FDA for XGEVA® sBLA for Prevention of Bone Metastases
|
| Apr. 25, 2012 |
Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
|
| Apr. 24, 2012 |
Amgen's First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61
|
| Apr. 23, 2012 |
A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)
|
| Apr. 19, 2012 |
Amgen Announces Webcast of 2012 First Quarter Financial Results
|
| Apr. 10, 2012 |
Amgen to Acquire Privately Held KAI Pharmaceuticals
|
| Apr. 4, 2012 |
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
|
| Apr. 2, 2012 |
Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio
|
| Mar. 28, 2012 |
Amgen Announces Phase 2 Study Results for Brodalumab in Moderate to Severe Plaque Psoriasis Published in the New England Journal of Medicine
|
| Mar. 25, 2012 |
Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b Study
|
| Mar. 15, 2012 |
Amgen Announces 2012 Second Quarter Dividend
|
| Mar. 7, 2012 |
Amgen Completes Tender Offer for Outstanding Shares of Micromet, Inc.
|
| Mar. 6, 2012 |
Schwartz Center Receives $500,000 Grant from the Amgen Foundation
|
| Mar. 2, 2012 |
Amgen Announces Initial Results of Tender Offer for Outstanding Shares of Micromet, Inc. and Commencement of Subsequent Offering Period
|
| Feb. 29, 2012 |
Amgen to Present at the Cowen and Company 32nd Annual Healthcare Conference
|
| Feb. 28, 2012 |
Amgen and European Schoolnet Launch New Professional Development Initiative for Life Science Teachers
|
| Feb. 23, 2012 |
Amgen to Present at the Citi 2012 Global Healthcare Conference
|
| Feb. 21, 2012 |
CURE Magazine Teams up with Amgen Oncology and Breakaway from Cancer® to Launch 2012 Extraordinary Healer Award for Oncology Nursing
|
| Feb. 15, 2012 |
Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet
|
| Feb. 14, 2012 |
Amgen Names Michael Severino, M.D., Senior Vice President, Global Development and Corporate Chief Medical Officer
|
| Feb. 13, 2012 |
Amgen to Present at the Leerink Swann Global Healthcare Conference
|
| Feb. 8, 2012 |
Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee Meeting
|
| Jan. 26, 2012 |
Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion and Adjusted Earnings Per Share (EPS) Increased 2 Percent to $5.33
|
| Jan. 26, 2012 |
Amgen to Acquire Micromet
|
| Jan. 24, 2012 |
Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
|
| Jan. 4, 2012 |
Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
|
|
|
|
|
|
|
|
|
|
|
|
